DNA methylation aberrancies as a guide for surveillance and treatment of human cancers

Epigenetics

Volumn 12, Issue 6, 2017, Pages 416-432

  Liang, Gangning ^a   Weisenberger, Daniel J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; chromatin; DNA demethylation; DNA methylation; DNA methylation inhibitors and epigenetic therapy; DNA methyltransferase; histone modification; TET

Indexed keywords

ARID1A PROTEIN; ARID1B PROTEIN; AZACITIDINE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EHMT2 PROTEIN; HISTONE LYSINE METHYLTRANSFERASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; KDM1A PROTEIN; KDM5C PROTEIN; KDM5D PROTEIN; KMD6A PROTEIN; KMT2A PROTEIN; KMT2B PROTEIN; KMT2C PROTEIN; KMT2D PROTEIN; MEMBRANE PROTEIN; MICRORNA; SETD2 PROTEIN; SUZ12 PROTEIN; TET1 PROTEIN; TET2 PROTEIN; TET3 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZEBULARINE; CHROMATIN;

BLADDER CANCER; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CHROMATIN STRUCTURE; COLON CANCER; DNA METHYLATION; ENDOMETRIUM CANCER; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GLIOMA; HISTONE MODIFICATION; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROSTATE CANCER; RECEPTOR UPREGULATION; REVIEW; SOMATIC MUTATION; STOMACH CANCER; TREATMENT OUTCOME; BIOSYNTHESIS; CHROMATIN; CPG ISLAND; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; IMMUNOTHERAPY; NEOPLASMS; PATHOLOGY; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

CHROMATIN; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOTHERAPY; MICRORNAS; NEOPLASMS; PROMOTER REGIONS, GENETIC;

EID: 85021434262     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2017.1311434     Document Type: Review

References (150)

1. Weisenberger DJ, Brown PJ. Network and consortia for epigenetic drug discovery. In:Egger G, Arimondo P, editors. Drug Discovery in Cancer Epigenetics. Waltham, MAUSA:Academic Press; 2016. p 143-162
2. Prasad V. Perspective:The precision-oncology illusion. Nature 2016; 537(7619):S63; PMID:27602743; https://doi.org/10.1038/537S63a
3. Klauschen F, Andreeff M, Keilholz U, Dietel M, Stenzinger A. The combinatorial complexity of cancer precision medicine. Oncoscience 2014; 1(7):504-9; PMID:25594052; https://doi.org/10.18632/oncoscience.66
4. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014; 158(4):929-44; PMID:25109877; https://doi.org/10.1016/j.cell.2014.06.049
5. Witte T, Plass C, Gerhauser C. Pan-cancer patterns of DNA methylation. Genome Med 2014; 6(8):66; PMID:25473433; https://doi.org/10.1186/s13073-014-0066-6
6. Jones PA. Functions of DNA methylation:islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13(7):484-92; PMID:22641018; https://doi.org/10.1038/nrg3230
7. Robertson KD, Jones PA. DNA methylation:past, present and future directions. Carcinogenesis 2000; 21(3):461-7; PMID:10688866; https://doi.org/10.1093/carcin/21.3.461
8. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011; 25(10):1010-22; PMID:21576262; https://doi.org/10.1101/gad.2037511
9. Ehrlich M, Wang RY. 5-Methylcytosine in eukaryotic DNA. Science 1981; 212(4501):1350-7; PMID:6262918; https://doi.org/10.1126/science.6262918
10. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301:89-92; PMID:6185846; https://doi.org/10.1038/301089a0
11. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983; 11:6883-6894; PMID:6314264; https://doi.org/10.1093/nar/11.19.6883
12. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 2014; 26(4):577-90; PMID:25263941; https://doi.org/10.1016/j.ccr.2014.07.028
13. De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, Yang X, Liang G, Jones PA. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012; 21(5):655-67; PMID:22624715; https://doi.org/10.1016/j.ccr.2012.03.045
14. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22(2):271-82; PMID:21659424; https://doi.org/10.1101/gr.117523.110
15. Lay FD, Liu Y, Kelly TK, Witt H, Farnham PJ, Jones PA, Berman BP. The role of DNA methylation in directing the functional organization of the cancer epigenome. Genome Res 2015; 25(4):467-77; PMID:25747664; https://doi.org/10.1101/gr.183368.114
16. Becket E, Chopra S, Duymich CE, Lin JJ, You JS, Pandiyan K, Nichols PW, Siegmund KD, Charlet J, Weisenberger DJ, et al. Identification of DNA methylation-independent epigenetic events underlying clear cell renal cell carcinoma. Cancer Res 2016; 76(7):1954-64; PMID:26759245; https://doi.org/10.1158/0008-5472.CAN-15-2622
17. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3(4):253-66; PMID:12671664; https://doi.org/10.1038/nrc1045
18. How Kit A, Nielsen HM, Tost J. DNA methylation based biomarkers:practical considerations and applications. Biochimie 2012; 94(11):2314-37; PMID:22847185; https://doi.org/10.1016/j.biochi.2012.07.014
19. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007; 3(9):1709-23; PMID:17892325; https://doi.org/10.1371/journal.pgen.0030157
20. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96(15):8681-6; PMID:10411935; https://doi.org/10.1073/pnas.96.15.8681
21. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38(7):787-93; PMID:16804544; https://doi.org/10.1038/ng1834
22. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58(1):90-6; PMID:18832519; https://doi.org/10.1136/gut.2008.155473
23. Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, Kim HC, Park CK, Lee SH, Kim KM, et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011; 11:344; PMID:21827707; https://doi.org/10.1186/1471-2407-11-344
24. Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol 2013; 13:36; PMID:23446022; https://doi.org/10.1186/1471-230X-13-36
25. Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Jr, Emond MJ, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 2014; 147(3):637-45; PMID:24859205; https://doi.org/10.1053/j.gastro.2014.05.009
26. Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015; 148(1):77-87 e2; PMID:25280443; https://doi.org/10.1053/j.gastro.2014.09.038
27. Kang KJ, Min BH, Ryu KJ, Kim KM, Chang DK, Kim JJ, Rhee JC, Kim YH. The role of the CpG island methylator phenotype on survival outcome in colon cancer. Gut Liver 2015; 9(2):202-7; PMID:25167802; https://doi.org/10.5009/gnl13352
28. Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients:a systematic review and meta-analysis. Ann Oncol 2014; 25(12):2314-27; PMID:24718889; https://doi.org/10.1093/annonc/mdu149
29. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17(5):510-22; PMID:20399149; https://doi.org/10.1016/j.ccr.2010.03.017
30. Cancer Genome Atlas Research Network T. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490(7418):61-70; PMID:23000897; https://doi.org/10.1038/nature11412
31. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 2011; 3(75):75ra25; PMID:21430268; https://doi.org/10.1126/scitranslmed.3001875
32. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497(7447):67-73; PMID:23636398; https://doi.org/10.1038/nature12113
33. Zhang QY, Yi DQ, Zhou L, Zhang DH, Zhou TM. Status and significance of CpG island methylator phenotype in endometrial cancer. Gynecol Obstet Invest 2011; 72(3):183-91; PMID:21968189; https://doi.org/10.1159/000324496
34. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59(21):5438-42; PMID:10554013
35. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11(2 Pt 1):656-63; PMID:15701853
36. Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, Hosokawa M, Shinomura Y, Imai K, Tokino T. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106(7):1467-79; PMID:16518809; https://doi.org/10.1002/cncr.21789
37. Chang MS, Uozaki H, Chong JM, Ushiku T, Sakuma K, Ishikawa S, Hino R, Barua RR, Iwasaki Y, Arai K, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 2006; 12(10):2995-3002; PMID:16707594; https://doi.org/10.1158/1078-0432.CCR-05-1601
38. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513(7517):202-9; PMID:25079317; https://doi.org/10.1038/nature13480
39. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499(7456):43-9; PMID:23792563; https://doi.org/10.1038/nature12222
40. Wei JH, Haddad A, Wu KJ, Zhao HW, Kapur P, Zhang ZL, Zhao LY, Chen ZH, Zhou YY, Zhou JC, et al. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nat Commun 2015; 6:8699; PMID:26515236; https://doi.org/10.1038/ncomms9699
41. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 1984; 81(22):6993-7; PMID:6209710; https://doi.org/10.1073/pnas.81.22.6993
42. Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009; 10(11):805-11; PMID:19789556; https://doi.org/10.1038/nrg2651
43. Barau J, Teissandier A, Zamudio N, Roy S, Nalesso V, Herault Y, Guillou F, Bourc'his D. The DNA methyltransferase DNMT3C protects male germ cells from transposon activity. Science 2016; 354(6314):909-912; PMID:27856912; https://doi.org/10.1126/science.aah5143
44. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416(6880):552-6; PMID:11932749; https://doi.org/10.1038/416552a
45. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000; 404(6781):1003-7; PMID:10801130; https://doi.org/10.1038/35010000
46. Egger G, Jeong S, Escobar SG, Cortez CC, Li TW, Saito Y, Yoo CB, Jones PA, Liang G. Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A 2006; 103(38):14080-5; PMID:16963560; https://doi.org/10.1073/pnas.0604602103
47. Chen T, Ueda Y, Xie S, Li E. A novel Dnmt3a isoform produced from an alternative promoter localizes to euchromatin and its expression correlates with active de novo methylation. J Biol Chem 2002; 277(41):38746-54; PMID:12138111; https://doi.org/10.1074/jbc.M205312200
48. Nimura K, Ishida C, Koriyama H, Hata K, Yamanaka S, Li E, Ura K, Kaneda Y. Dnmt3a2 targets endogenous Dnmt3L to ES cell chromatin and induces regional DNA methylation. Genes Cells 2006; 11(10):1225-37; PMID:16999741; https://doi.org/10.1111/j.1365-2443.2006.01012.x
49. Jeong S, Liang G, Sharma S, Lin JC, Choi SH, Han H, Yoo CB, Egger G, Yang AS, Jones PA. Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol 2009; 29(19):5366-76; PMID:19620278; https://doi.org/10.1128/MCB.00484-09
50. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363(25):2424-33; PMID:21067377; https://doi.org/10.1056/NEJMoa1005143
51. Cancer Genome Atlas Research Network T. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368(22):2059-2074; PMID:23634996; https://doi.org/10.1056/NEJMoa1301689
52. Aoki A, Suetake I, Miyagawa J, Fujio T, Chijiwa T, Sasaki H, Tajima S. Enzymatic properties of de novo-type mouse DNA (cytosine-5) methyltransferases. Nucleic Acids Res 2001; 29(17):3506-12; PMID:11522819; https://doi.org/10.1093/nar/29.17.3506
53. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci U S A 2002; 99(15):10060-5; PMID:12110732; https://doi.org/10.1073/pnas.152121799
54. Ostler KR, Davis EM, Payne SL, Gosalia BB, Exposito-Cespedes J, Le Beau MM, Godley LA. Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene 2007; 26(38):5553-63; PMID:17353906; https://doi.org/10.1038/sj.onc.1210351
55. Gopalakrishnan S, Van Emburgh BO, Shan J, Su Z, Fields CR, Vieweg J, Hamazaki T, Schwartz PH, Terada N, Robertson KD. A novel DNMT3B splice variant expressed in tumor and pluripotent cells modulates genomic DNA methylation patterns and displays altered DNA binding. Mol Cancer Res 2009; 7(10):1622-34; PMID:19825994; https://doi.org/10.1158/1541-7786.MCR-09-0018
56. Gordon CA, Hartono SR, Chedin F. Inactive DNMT3B splice variants modulate de novo DNA methylation. PLoS One 2013; 8(7):e69486; PMID:23894490; https://doi.org/10.1371/journal.pone.0069486
57. Shao G, Zhang R, Zhang S, Jiang S, Liu Y, Zhang W, Zhang Y, Li J, Gong K, Hu XR, et al. Splice variants DNMT3B4 and DNMT3B7 overexpression inhibit cell proliferation in 293A cell line. In Vitro Cell Dev Biol Anim 2013; 49(5):386-94; PMID:23636939; https://doi.org/10.1007/s11626-013-9619-z
58. Duymich CE, Charlet J, Yang X, Jones PA, Liang G. DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. Nat Commun 2016; 7:11453; PMID:27121154; https://doi.org/10.1038/ncomms11453
59. Sharma S, De Carvalho DD, Jeong S, Jones PA, Liang G. Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet 2011; 7(2):e1001286; PMID:21304883; https://doi.org/10.1371/journal.pgen.1001286
60. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 1999; 397(6720):579-83; PMID:10050851; https://doi.org/10.1038/17533
61. Ramchandani S, Bhattacharya SK, Cervoni N, Szyf M. DNA methylation is a reversible biological signal. Proc Natl Acad Sci U S A 1999; 96(11):6107-12; PMID:10339549; https://doi.org/10.1073/pnas.96.11.6107
62. Wolffe AP, Jones PL, Wade PA. DNA demethylation. Proc Natl Acad Sci U S A 1999; 96(11):5894-6; PMID:10339513; https://doi.org/10.1073/pnas.96.11.5894
63. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16(1):6-21; PMID:11782440; https://doi.org/10.1101/gad.947102
64. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324(5929):930-5; PMID:19372391; https://doi.org/10.1126/science.1170116
65. Blaschke K, Ebata KT, Karimi MM, Zepeda-Martinez JA, Goyal P, Mahapatra S, Tam A, Laird DJ, Hirst M, Rao A, et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 2013; 500(7461):222-6; PMID:23812591; https://doi.org/10.1038/nature12362
66. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002; 62(14):4075-80; PMID:12124344
67. Iyer LM, Tahiliani M, Rao A, Aravind L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 2009; 8(11):1698-710; PMID:19411852; https://doi.org/10.4161/cc.8.11.8580
68. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011; 333(6047):1300-3; PMID:21778364; https://doi.org/10.1126/science.1210597
69. Booth MJ, Branco MR, Ficz G, Oxley D, Krueger F, Reik W, Balasubramanian S. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 2012; 336(6083):934-7; PMID:22539555; https://doi.org/10.1126/science.1220671
70. Pfeifer GP, Kadam S, Jin SG. 5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin 2013; 6(1):10; PMID:23634848; https://doi.org/10.1186/1756-8935-6-10
71. Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med 2005; 19(1):17-20; PMID:15690864; https://doi.org/10.1191/0269216305pm970oa
72. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321(5897):1807-12; PMID:18772396; https://doi.org/10.1126/science.1164382
73. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013; 13(5):345; PMID:23532369; https://doi.org/10.1007/s11910-013-0345-4
74. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010; 465(7300):966; PMID:20559394; https://doi.org/10.1038/nature09132
75. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19(1):17-30; PMID:21251613; https://doi.org/10.1016/j.ccr.2010.12.014
76. Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, Chi JT, Bigner DD, Vertino PM, Yan H. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 2012; 22(12):2339-55; PMID:22899282; https://doi.org/10.1101/gr.132738.111
77. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483(7390):479-83; PMID:22343889; https://doi.org/10.1038/nature10866
78. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361(11):1058-66; PMID:19657110; https://doi.org/10.1056/NEJMoa0903840
79. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17(3):225-34; PMID:20171147; https://doi.org/10.1016/j.ccr.2010.01.020
80. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18(6):553-67; PMID:21130701; https://doi.org/10.1016/j.ccr.2010.11.015
81. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia:a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28(14):2348-55; PMID:20368543; https://doi.org/10.1200/JCO.2009.27.3730
82. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24(7):1302-9; https://doi.org/10.1038/leu.2010.113
83. Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, Ottmann O, Lubbert M, Heit W, Kanz L, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia:SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010; 28(14):2356-64; PMID:20368538; https://doi.org/10.1200/JCO.2009.27.6899
84. Cancer Genome Atlas Research Network T. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487(7407):330-7; PMID:22810696; https://doi.org/10.1038/nature11252
85. Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell 2015; 161(7):1681-96; PMID:26091043; https://doi.org/10.1016/j.cell.2015.05.044
86. Margueron R, Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet 2010; 11(4):285-96; PMID:20300089; https://doi.org/10.1038/nrg2752
87. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293(5532):1074-80; PMID:11498575; https://doi.org/10.1126/science.1063127
88. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011; 21(3):381-95; PMID:21321607; https://doi.org/10.1038/cr.2011.22
89. Hon GC, Hawkins RD, Ren B. Predictive chromatin signatures in the mammalian genome. Hum Mol Genet 2009; 18(R2):R195-201; PMID:19808796; https://doi.org/10.1093/hmg/ddp409
90. Heinz S, Romanoski CE, Benner C, Glass CK. The selection and function of cell type-specific enhancers. Nat Rev Mol Cell Biol 2015; 16(3):144-54; PMID:25650801; https://doi.org/10.1038/nrm3949
91. Cedar H, Bergman Y. Linking DNA methylation and histone modification:patterns and paradigms. Nat Rev Genet 2009; 10(5):295-304; PMID:19308066; https://doi.org/10.1038/nrg2540
92. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125(2):315-26; PMID:16630819; https://doi.org/10.1016/j.cell.2006.02.041
93. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007; 39(2):237-42; PMID:17211412; https://doi.org/10.1038/ng1972
94. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39(2):232-6; PMID:17200670; https://doi.org/10.1038/ng1950
95. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007; 39(2):157-8; PMID:17200673; https://doi.org/10.1038/ng1941
96. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, Lin JC, Liang G, Jones PA, Tanay A. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A 2008; 105(35):12979-84; PMID:18753622; https://doi.org/10.1073/pnas.0806437105
97. Pandiyan K, You JS, Yang X, Dai C, Zhou XJ, Baylin SB, Jones PA, Liang G. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res 2013; 41(7):3973-85; PMID:23408854; https://doi.org/10.1093/nar/gkt077
98. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013; 153(1):38-55; PMID:23540689; https://doi.org/10.1016/j.cell.2013.03.008
99. Shimbo T, Wade PA. Proteins that read DNA methylation. In:Jeltsch A, Jurkowska RA, editors. Advances in Experimental Medicine and Biology. DNA methyltransferases - Role and Function. Volume 945:Springer; 2016. p 303-20
100. Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol 2014; 24(16):R762-76; PMID:25137592; https://doi.org/10.1016/j.cub.2014.06.043
101. Iorio MV, Croce CM. MicroRNA dysregulation in cancer:diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4(3):143-59; PMID:22351564; https://doi.org/10.1002/emmm.201100209
102. Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 2012; 31(13):1609-22; PMID:21860412; https://doi.org/10.1038/onc.2011.354
103. Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, Tagliaferri P, Tassone P. miR-29s:a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget 2015; 6(15):12837-61; PMID:25968566; https://doi.org/10.18632/oncotarget.3805
104. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9(6):435-43; PMID:16766263; https://doi.org/10.1016/j.ccr.2006.04.020
105. Damiano V, Brisotto G, Borgna S, di Gennaro A, Armellin M, Perin T, Guardascione M, Maestro R, Santarosa M. Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1. Genes Chromosomes Cancer 2017; 56(2):147-158; PMID:27717206; https://doi.org/10.1002/gcc.22422
106. Zheng K, Zhou X, Yu J, Li Q, Wang H, Li M, Shao Z, Zhang F, Luo Y, Shen Z, et al. Epigenetic silencing of miR-490-3p promotes development of an aggressive colorectal cancer phenotype through activation of the Wnt/beta-catenin signaling pathway. Cancer Lett 2016; 376(1):178-87; PMID:27037061; https://doi.org/10.1016/j.canlet.2016.03.024
107. Li HP, Huang HY, Lai YR, Huang JX, Chang KP, Hsueh C, Chang YS. Silencing of miRNA-148a by hypermethylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma. Oncotarget 2014; 5(17):7610-24; PMID:25277193; https://doi.org/10.18632/oncotarget.2282
108. Chen BF, Suen YK, Gu S, Li L, Chan WY. A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor. Sci Rep 2014; 4:6413; PMID:25231260; https://doi.org/10.1038/srep06413
109. Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W, Zhou X, Jones PA. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009; 69(6):2623-9; PMID:19258506; https://doi.org/10.1158/0008-5472.CAN-08-3114
110. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007; 104(40):15805-10; PMID:17890317; https://doi.org/10.1073/pnas.0707628104
111. Shortt J, Ott CJ, Johnstone RW, Bradner JE. A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer 2017; 17(3):160-183; PMID:28228643; https://doi.org/10.1038/nrc.2016.148
112. Raynal NJ-M, Issa JP. DNA methyltransferase inhibitors. In:Egger G, Arimondo P, editors. Drug Discovery in Cancer Epigenetics. Waltham, MA:Academic Press; 2016. p 169-190
113. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20(1):85-93; PMID:6156004; https://doi.org/10.1016/0092-8674(80)90237-8
114. Chen JC, Goldhamer DJ. Transcriptional mechanisms regulating MyoD expression in the mouse. Cell Tissue Res 1999; 296(1):213-9; PMID:10199981; https://doi.org/10.1007/s004410051282
115. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005; 25(11):4727-41; PMID:15899874; https://doi.org/10.1128/MCB.25.11.4727-4741.2005
116. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21(35):5483-95; PMID:12154409; https://doi.org/10.1038/sj.onc.1205699
117. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine:a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002; 321(4):591-9; PMID:12206775; https://doi.org/10.1016/S0022-2836(02)00676-9
118. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004; 6(2):151-8; PMID:15324698; https://doi.org/10.1016/j.ccr.2004.06.023
119. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003; 95(5):399-409; PMID:12618505; https://doi.org/10.1093/jnci/95.5.399
120. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004; 24(3):1270-8; PMID:14729971; https://doi.org/10.1128/MCB.24.3.1270-1278.2004
121. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 2005; 11(12):4571-9; PMID:15958643; https://doi.org/10.1158/1078-0432.CCR-05-0050
122. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, Lyubimov AV, Chen YF, D'Argenio DZ, Egorin MJ. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 2005; 11(10):3862-8; PMID:15897587; https://doi.org/10.1158/1078-0432.CCR-04-2406
123. Chuang JC, Warner SL, Vollmer D, Vankayalapati H, Redkar S, Bearss DJ, Qiu X, Yoo CB, Jones PA. S110, a 5-Aza-2′-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther 2010; 9(5):1443-50; PMID:20442312; https://doi.org/10.1158/1535-7163.MCT-09-1048
124. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S, Jones PA. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007; 67(13):6400-8; PMID:17616700; https://doi.org/10.1158/0008-5472.CAN-07-0251
125. Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol Oncol 2015; 9(9):1799-814; PMID:26160429; https://doi.org/10.1016/j.molonc.2015.06.002
126. Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia:a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 2015; 16(9):1099-110; PMID:26296954; https://doi.org/10.1016/S1470-2045(15)00038-8
127. Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS, Jones PA. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 2005; 4(10):1515-20; PMID:16227400; https://doi.org/10.1158/1535-7163.MCT-05-0172
128. Velicescu M, Weisenberger DJ, Gonzales FA, Tsai YC, Nguyen CT, Jones PA. Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res 2002; 62(8):2378-84; PMID:11956100
129. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2 Suppl 1:S4-11; PMID:16341240; https://doi.org/10.1038/ncponc0354
130. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10):997-1003; PMID:15758010; https://doi.org/10.1056/NEJMoa043331
131. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012; 21(3):430-46; PMID:22439938; https://doi.org/10.1016/j.ccr.2011.12.029
132. Kasinathan S, Henikoff S. 5-Aza-CdR delivers a gene body blow. Cancer Cell 2014; 26(4):449-51; PMID:25314073; https://doi.org/10.1016/j.ccell.2014.09.004
133. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 2016; 164(5):1073; PMID:27064190; https://doi.org/10.1016/j.cell.2015.10.020
134. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, et al. DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015; 162(5):961-73; PMID:26317465; https://doi.org/10.1016/j.cell.2015.07.056
135. Liu M, Ohtani H, Zhou W, Orskov AD, Charlet J, Zhang YW, Shen H, Baylin SB, Liang G, Gronbaek K, et al. Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine. Proc Natl Acad Sci U S A 2016; 113(37):10238-44; PMID:27573823; https://doi.org/10.1073/pnas.1612262113
136. Ikehata M, Ogawa M, Yamada Y, Tanaka S, Ueda K, Iwakawa S. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells. Biol Pharm Bull 2014; 37(1):67-73; PMID:24172061; https://doi.org/10.1248/bpb.b13-00574
137. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 2013; 4(11):2067-79; PMID:24162015; https://doi.org/10.18632/oncotarget.1542
138. Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, Bellani M, Zou Y, Singh ZN, Duong VH, et al. Enhancing the cytotoxic effects of PARP Inhibitors with DNA demethylating agents - a potential therapy for cancer. Cancer Cell 2016; 30(4):637-650; PMID:27728808; https://doi.org/10.1016/j.ccell.2016.09.002
139. Ahuja N, Sharma AR, Baylin SB. Epigenetic therapeutics:a new weapon in the war against cancer. Annu Rev Med 2016; 67:73-89; PMID:26768237; https://doi.org/10.1146/annurev-med-111314-035900
140. Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Gotze KS. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics 2016; 8:71; PMID:27330573; https://doi.org/10.1186/s13148-016-0237-y
141. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28(4):562-9; PMID:20026804; https://doi.org/10.1200/JCO.2009.23.8329
142. Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, Schreder M, Tinchon C, Sliwa T, Lang A, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia:results from the Austrian Azacitidine Registry of the AGMT-study group. Ann Hematol 2014; 93(11):1825-38; PMID:24951123; https://doi.org/10.1007/s00277-014-2126-9
143. Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, et al. Azacitidine in untreated acute myeloid leukemia:a report on 149 patients. Am J Hematol 2014; 89(4):410-6; PMID:24375487; https://doi.org/10.1002/ajh.23654
144. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015; 126(3):291-9; PMID:25987659; https://doi.org/10.1182/blood-2015-01-621664
145. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011; 1(7):598-607; PMID:22586682; https://doi.org/10.1158/2159-8290.CD-11-0214
146. Connolly R, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater S, Powers P, Wolff AC, Fetting JH, et al. Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat:a phase ii national cancer institute/stand up to cancer study. Clin Cancer Res 2016; PMID:27979916; https://doi.org/10.1158/1078-0432.CCR-16-1729
147. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011; 117(8):1661-9; PMID:21472713; https://doi.org/10.1002/cncr.25701
148. Scartozzi M, Bearzi I, Mandolesi A, Giampieri R, Faloppi L, Galizia E, Loupakis F, Zaniboni A, Zorzi F, Biscotti T, et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer 2011; 104(11):1786-90; PMID:21559018; https://doi.org/10.1038/bjc.2011.161
149. Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs 2013; 31(5):1257-64; PMID:23504398; https://doi.org/10.1007/s10637-013-9947-6
150. Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, et al. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat; a phase 2 consortium/stand Up 2 cancer study. Oncotarget 2017; PMID:28186961; https://doi.org/10.18632/oncotarget.15108